NT-3 targeting genetically modified allogeneic sertoli cells (MandalMed)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameNT-3 targeting genetically modified allogeneic sertoli cells (MandalMed)
Drug Alias Nameregenerative cell therapy (MandalMed)neurotrophin-3 stimulator (MandalMed)NT-3 stimulator (MandalMed)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionNeurotrophin-3 ligand
TargetsNeurotrophin-3
Therapy Area/IndicationsSpinal Cord InjuriesBrain Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMandalMed Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMandalMed Inc
Active IndicationsN/A
Inactive IndicationsSpinal Cord InjuriesBrain Injuries

Other Information

ATC CodeN/A
Related LinksN/A